D. McKenzie

发表

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

G. Mufti, B. Quesnel, G. Garcia-Manero, 2008 .

Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

R. Larson, B. Peterson, J. Holland, 2005 .

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

L. Silverman, G. Mufti, P. Fenaux, 2008 .

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

S. Gore, P. Fenaux, E. Hellström-Lindberg, 2008, Ecancermedicalscience.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

R. Larson, B. Peterson, L. Silverman, 2005 .

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Metastatic extramammary Paget's disease: Dramatic response to combined modality treatment

E. Crawford, L. Balducci, T. Khansur, 1988, Journal of surgical oncology.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

R. Larson, B. Peterson, J. Holland, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, Critical reviews in oncology/hematology.

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

R. Larson, B. Peterson, L. Silverman, 2005 .

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

H. Heidbuchel, D. Atar, J. Le Heuzey, 2021, BMC Medicine.

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .